Acta Medica Okayama volume73 issue3
2019-06 発行
Makimoto, Go
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nishimori, Hisakazu
Department of Hematology and Oncology, Okayama University Hospital
Kondo, Reiko
Okayama University Medical School
Yanai, Hiroyuki
Department of Pathology, Okayama University Hospital
Sugimoto, Morito
Department of Urology, Okayama University Hospital
Oda, Naohiro
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kubo, Toshio
Center for Clinical Oncology, Okayama University Hospital
Hotta, Katsuyuki
Center of Innovative Clinical Medicine, Okayama University Hospital
Tabata, Masahiro
Center for Clinical Oncology, Okayama University Hospital
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Urothelial carcinoma usually presents with hematuria, but cases of multiple lymphadenopathy with elevated S-pancreas-1 antigen (SPan-1) levels have not been reported. A 62-year-old Japanese man with lymphadenopathies was diagnosed with an adenocarcinoma of unknown origin and transferred to our hospital for further diagnosis. Serum carbohydrate antigen 19-9 and SPan-1 levels were extremely elevated. Uroplakin III immunostaining was positive in the inguinal lymph node, and cystoscopy revealed the presence of invasive urothelial carcinoma. Treatment with cisplatin and gemcitabine promoted a complete metabolic response for > 4 years. The detection of uroplakin III and serum SPan-1 might help diagnose urothelial carcinoma.
urothelial carcinoma
uroplakin III
s-pancreas-1 antigen
carbohydrate antigen 19-9
chemotherapy
